Only 31% of patients with prostate cancer receiving radiation therapy had a successful CT simulation on the first attempt, while more than half required multiple scans on the same day and nearly 17% ...
An imaging test could safely halve the number of people who need a biopsy for suspected prostate cancer following ...
Scans that make prostate cancer cells glow can eliminate the need for invasive biopsies and cut false positive—and they're ...
New research in the February 2026 issue of JNCCN-Journal of the National Comprehensive Cancer Networkfound that incorporating information from prostate-specific membrane antigen (PSMA) PET/CT scans ...
More than 70% of patients with biochemically recurrent prostate cancer remained metastasis-free 5 years after PSMA PET/CT-guided salvage radiation therapy. Whole-pelvis radiation significantly ...
Prostate cancer is one of the most common cancers worldwide and remains a significant cause of cancer-related death. With increasing life expectancy, its incidence is projected to rise steadily in the ...
FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results